North Sound Capital LLC v. Merck & Co IncNorth Sound Capital LLC v. Merck & Co Inc
Daniel J. Kramer (argued), Theodore V. Wells, Jr., Charles E. Davidow, Daniel J. Leffell, Daniel J. Juceam, Paul, Weiss, Rifkind, Wharton & Garrison, 1285 Avenue of the Americas, New York, NY 10019-6064, William H. Trousdale, Brian M. English, Tomkins, McGuire, Wachenfeld & Barry, 3 Becker Fаrm Road, Fourth Floor, Roseland, NJ 07065-1726, Attorneys for Appellants
Scott L. Nelson, Allison M. Zieve, Public Citizen Litigation Group, 1600 20th Street, N.W., Washington, DC 20009, Max W. Berger, Salvatore J. Graziano, Bernstein Litowitz Berger & Grossman, 1251 Avenue of the Americas, 44th Floor, New York, NY 10020, Blair Nicholas, Bernstein Litowitz Berger & Grossman, 12481 High Bluff Drive, Suite 300, San Diego, CA 92130, Ira D. Hammerman, Kevin M. Carrоll, Securities Industry and Financial Markets Association, 1399 New York Avenue, N.W., Washington, DC 20005, Jared M. Gerber, Lewis J. Liman, Cleary Gottlieb Steen & Hamilton, One Liberty Plaza, New York, NY 10006, Daniel P. Chiploch, Lieff Cabraser Heimann & Bernstein, 250 Hudson Street, 8th Floor, New York, NY 10013, Darren Robbins, Joseph D. Daley, Robbins Geller Rudman & Dowd, 655 West Broadway, Suite 1900, San Diego, CA 92501, Tejinder Singh, Thomas C. Goldstein, Goldstein & Russell, 7475 Wisconsin Avenue, Suite 850, Bethesda, MD 20814, Attorneys for amici curiae
OPINION1
GREENBERG, Circuit Judge.
I. INTRODUCTION
In American Pipe & Construction Co. v. Utah, 414 U.S. 538, 94 S.Ct. 756, 38 L.Ed.2d 713 (1974) (”American Pipe“), the Supreme Court established a class action tolling rule providing for tolling of the time for bringing lawsuits by unnamed members of a class in a putative class action during the time that a district court was deciding whether to certify the plaintiff class. In the cases now before us on Merck and Co.‘s (“Merck“) and Merck and Co. as successor to Schering Plough Pharmaceuticals‘s (“Schering“) (together “appellants“) consolidated appeals, we determine whether, in this action that GIC Private Limited and North Sound Capital LLC (“appellees“) and other plaintiffs brought under the Securities Exchange Act of 1934 (“Exchange Act“) against appellants, the American Pipe rule can be applied to toll the time for bringing actions otherwise beyond the time allowed by statutes of repose. It is undisputed that, in the absence of tolling, appellees’ actions would be untimely as appellees initiated their cases beyond that time. It is now clear that in the light of California Public Employees’ Retirement System v. ANZ Securities, Inc., — U.S. —, 137 S.Ct. 2042, 198 L.Ed.2d 584 (2017), that the American Pipe tolling rule cannot be invoked to toll the running of time under the statutes of repose at issue in these cases and that appellees’ Exchange Act claims therefore were untimely. Accordingly, we will reverse an order that the District Court entered on August 26, 2015, denying appellants’ motions to dismiss appellees’ Exchange Act cases and will remand the cases to the District Court to dismiss appellees’ cases insofar as they assert Exchange Act claims.
II. JURISDICTION AND STANDARD OF REVIEW
The District Court had jurisdiction under
III. BACKGROUND3
A. The ENHANCE Trial
In 2002, Merck and Schering entered into a joint venture for the purpose of
The ENHANCE trial ran from August 2002 to August 2006 but was unsuccessful. According to appellees, notwithstanding the hurdles attributable to ENHANCE‘s experimental design, appellants аllegedly misrepresented Vytorin‘s prospects for clinical efficacy. Appellees claim that appellants made 17 misrepresentations concerning Vytorin, the last by Schering on November 19, 2007, and by Merck on January 30, 2008. They also allege that an individual defendant made sales of Schering stock bаsed on insider knowledge of the results of ENHANCE, the last insider transaction having been on May 1, 2007.
The final results of the ENHANCE trial became public between January and March 2008 and the ENHANCE data indicated that Vytorin did not produce any added benefit when compared to Zocor alone. Indeed, according to appellees, researchers characterized Vytorin‘s active ingredient as an “expensive placebo.” (JA 132, ¶ 142). Appellees assert that in the period immediately following the release of these results, Schering‘s “common stock price fell more than 52%, wiping out more than $23.63 billion in market capitalization, and the ... preferred stock price similarly fell more than 40% ... wiping out $1.039 billion in market capitalization.” (JA 216, ¶ 320) (emphasis in the original).
B. The Class Actions
After the results of ENHANCE became public in 2008, representative plaintiffs filed two putative class actions related to the test‘s failure, one against Merck and one agаinst Schering. See In re Schering-Plough Corp./ENHANCE Sec. Litig., No. 2:08-cv-00397 (DMC) (JAD), 2012 WL 4482032 (D.N.J. Sept. 25, 2012) (“Schering Class Action“); In re Merck & Co., Vytorin/Zetia Sec. Litig., No. 2:08-cv-02177 (DMC) (JAD), 2012 WL 4482041 (D.N.J. Sept. 25, 2012) (“Merck Class Action“). The District Court certified classes in both cases on September 25, 2012. See Schering Class Action, 2012 WL 4482032, at *1; Merck Class Action, 2012 WL 4482041, at *1. On December 28, 2012, the Court approved notices to be given to members of the proposed classes, and, in both cases permitted class members to opt-out of the classes until March 1, 2013. Ultimately the parties settled the class actions.
C. Appellees Opt-Out of the Class
Appellees North Sound Capital LLC and GIC Private Limited, both institutional investors, who were within the classes in the underlying actions, timely opted-out of the classes on March 1, 2013. Then appellees initiated four district court actions agаinst appellants on November 14, 2013, and January 14, 2014.5 In their essentially identical complaints, appellees alleged that
D. Appellants’ Motions to Dismiss and Petitions for Interlocutory Review
On November 17, 2014, appellants moved under
Appellees, in opposing dismissal of their actions in the District Court, asserted that
On August 26, 2015, the District Court denied appellants’ motions to dismiss. The Court first concluded that the time limitations in
As we set forth above, appellants filed a motion in the District Court seеking an order certifying the statute of repose questions to this Court for appeal pursuant to
- Whether the tolling rule set forth in American Pipe & Constr. Co. v. Utah, 414 U.S. 538, 94 S.Ct. 756, 38 L.Ed.2d 713 (1974) is “legal” or “equitable” in nature;
- Whether interpreting American Pipe & Constr. Co. v. Utah, 414 U.S. 538, 94 S.Ct. 756, 38 L.Ed.2d 713 (1974) tolling to extend the five-year statutes of repose under the Securities Exchange Act оf 1934 would abridge [appellants‘] substantive rights, enlarge [appellee]s’ substantive rights, or otherwise modify any substantive right within the meaning of the Rules Enabling Act,
28 U.S.C. § 2072(b) [.]
(JA 34). After the District Court entered the above order, appellants petitioned this Court for leave to file an interlocutory appeal and we granted their pеtition pursuant to
IV. DISCUSSION
When this case was before the District Court the outcome was not obvious. But
V. CONCLUSION
For the foregoing reasons, we will reverse the District Court‘s order of August 26, 2015, denying appellants’ motions to dismiss appellees’ Exchange Act claims, and will remand the cases to that Court for it to dismiss the Exchange Act claims as time-barred, and for further proceedings on the remaining issues.